Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to f…


CD3 as co-creator of drugs with academia and pharma

The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from academic ins…


Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…

POPULAR TAGS

Four times more funds for VIB

Written by DS on in the category news with the tags , .


The Flemish Government will increase the annual support for the VIB from 15 million to 59 million per year. "The VIB is the catalyst of the Flemish biotechnology sector. It's an excellent reference for Flanders as a knowledge region," says Flemish Minister for Economy and Innovation Philippe Muyters (N-VA), who signed the new agreement yesterday.

"We're in the Champions League of the sector. We are on the same level as MIT, Stanford and Oxford," says Jo Bury, business director of VIB. "To stay at the top, we need to invest. The greater our image, the easier it will be to attract top talent from around the world," he adds.

"The support of Flanders is important and significant. But Flanders gets much in return," continues Bury. VIB plays an important role in attracting foreign companies. For example, Yakult (probiotics) and Regenesys (stem cell medicine) developed activities in Flanders, as well as Argen-X (originally Dutch) and Biocartis (founded by Rudi Pauwels in Switzerland).

Currently, VIB is at the basis of 18 spin-offs. Ablynx is the most visible, with a market value of 750 million euros on the Brussels stock exchange. But there is also the diagnostics company Multiplicom, for which the US-based Agilent paid 68 million euros last year, a deal that provided the VIB, as one of the major shareholders, with a substantial capital injection of more than 10 million.

In addition, the VIB attracts national and international research fellowships and funds, as for example the Bill & Melinda Gates Foundation, sponsor of a malaria research. Also collaborations with many companies generate more budget. For example, the Leuven research group of Kevin Verstrepen works with AB InBev for the development of new beer yeasts. Also, Pfizer, Roche and Bayer works with the VIB.

Read more about: , .

RELATED ARTICLES
The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to f…


CD3 as co-creator of drugs with academia and pharma

The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from academic ins…


Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven V-Bio Ventures UGent Janssen Itera Life Science XpandInnovation Turnstone GSK Biowin Flanders.bio

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.